Literature DB >> 4748254

Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission.

E Frei, J K Luce, J F Gamble, C A Coltman, J J Constanzi, R W Talley, R W Monto, H E Wilson, J S Hewlett, F C Delaney, E A Gehan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4748254     DOI： 10.7326/0003-4819-79-3-376

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  15 in total

Review 1.  Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Authors:  Joachim Yahalom
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 2.  [Hodgkin's disease. Results in diagnosis and treatment (author's transl)].

Authors:  D Huhn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-04-17

3.  Acute leukemia in a patient cured of diffuse histiocytic lymphoma.

Authors:  J P Dutcher; P H Wiernik
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Randomised trial of two-drug and four-drug maintenance chemotherapy in advanced or recurrent Hodgkin's disease. Medical Research Council's working party on lymphomas.

Authors:  P G Smith; N Wald
Journal:  Br Med J       Date:  1979-04-28

5.  Combination chemotherapy.

Authors:  E Frei
Journal:  Proc R Soc Med       Date:  1974-06

6.  The treatment of advanced hodgkin's disease.

Authors:  D J Straus; B J Lee; B Koziner; L Z Nisce; C W Young; B D Clarkson
Journal:  Blut       Date:  1981-08

7.  [A modified MOPP regimen in the treatment of Hodgkin's disease stage III B and IV (author's transl)].

Authors:  F J Tigges; E Hiller; R M Schmülling; H D Waller; K Wilms
Journal:  Blut       Date:  1978-08-15

8.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06

9.  Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).

Authors:  D J Straus; J Myers; B Koziner; B J Lee; B D Clarkson
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 10.  Why Great Mitotic Inhibitors Make Poor Cancer Drugs.

Authors:  Victoria C Yan; Hannah E Butterfield; Anton H Poral; Matthew J Yan; Kristine L Yang; Cong-Dat Pham; Florian L Muller
Journal:  Trends Cancer       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.